

---

# Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial

---

Correction to: *Nature Medicine*  
<https://doi.org/10.1038/s41591-024-03450-4>,  
published online 22 January 2025.

<https://doi.org/10.1038/s41591-025-03666-y>

Published online: 26 March 2025

---

Lin Shen , Yanqiao Zhang, Ziyu Li , Xiaotian Zhang, Xiangyu Gao , Bo Liu, Yusheng Wang, Yi Ba, Ning Li, Ruixing Zhang, Jingdong Zhang, Ye Chen, Jian Chen, Mingzhu Huang, Yang Fu, Mulin Liu, Zheng Liu, Jun Zhao, Wei Li, Jia Wei , Changzheng Li, Nong Xu, Zengqing Guo, Bangwei Cao, Lian Liu, Peng Nie, Lixin Wan, Lili Sheng, Zhenyang Liu, Yifu He, Kangsheng Gu, Guowu Wu, Weibo Wang, Futong Zhang, Wensheng Qiu, Jun Guo, Jieer Ying, Hongming Pan, Huiting Xu, Yuan Yuan, Yuansong Bai, Zhenghua Wang, Jiye Xu, Xuehong Zhao, Hao Liu, Xizhi Zhang, Wenxiang Dai, Hongyan Xu, Ming Liu, Lin Xie, Yong Tang, Jianying Jin, Xiujuan Qu, Xuefeng Fang, Mingwei Huang, Hao Chen, Zhendong Zheng, Ying Wang, Daqing Wang, Xiaoqin Li, Guohua Yu, Haiyan Liu, Yongjian Zhou, Diansheng Zhong, Shan Zeng, Mafei Kang, Meiqing Wang, Yong Gao, Wenxin Li, Zejun Wang, Minghui Zhang, Jinghua Zhang, Qingshan Li, Shujuan Sun, Aimin Zang, Lizhu Lin, Ming Xie, Zhixiang Zhuang, Tao Zhang, Zhifang Yao, Dongmei Lu, Wei Liu, Mingxiu Hu, Zhongmin Maxwell Wang , Baiyong Li, Michelle Xia, Jiajia Zhang, Xiangji Ying, Drew M. Pardoll  & Jiafu Ji 

---

In the version of this article initially published, the labels “≥5” and “<5” were missing from the PD-L1 CPS at baseline (22C3) column in Fig. 1d; in Fig. 3a–c, the y-axis labels “PFS (%)” now replace overall survival “OS (%)” while in Fig. 3a, the hazard ratio value “0.53” now replaces the original “0.55.” The figures are updated in the HTML and PDF versions of the article.

© The Author(s), under exclusive licence to Springer Nature America, Inc. 2025